KROS vs. RCAT

Last updated Apr 1, 2026

Compare and contrast key facts about Keros Therapeutics, Inc. (KROS) and Red Cat Holdings, Inc. (RCAT).

Performance

KROS vs. RCAT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Keros Therapeutics, Inc. (KROS) and Red Cat Holdings, Inc. (RCAT). The values are adjusted to include any dividend payments, if applicable.

KROS vs. RCAT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
KROS Keros Therapeutics, Inc.	-45.78%	28.62%	-60.19%	-17.20%	-17.93%	-17.05%	251.29%
RCAT Red Cat Holdings, Inc.	65.07%	-38.29%	1,360.23%	-6.38%	-54.81%	-30.67%	300.00%

Fundamentals

Market Cap KROS : $417.96M RCAT : $1.56B
EPS KROS : $2.19 RCAT : -$0.71
PS Ratio KROS : 1.80 RCAT : 32.62
PB Ratio KROS : 1.38 RCAT : 6.36
Total Revenue (TTM) KROS : $244.06M RCAT : $40.73M
Gross Profit (TTM) KROS : $242.91M RCAT : $1.28M
EBITDA (TTM) KROS : $82.26M RCAT : -$60.91M

Returns By Period

In the year-to-date period, KROS achieves a -45.78% return, which is significantly lower than RCAT's 65.07% return.

KROS

• 1D: 3.37%
• 1M: -22.20%
• YTD: -45.78%
• 6M: -30.21%
• 1Y: 8.34%
• 3Y*: -36.29%
• 5Y*: -28.42%
• 10Y*: —

RCAT

• 1D: 12.94%
• 1M: 12.36%
• YTD: 65.07%
• 6M: 26.47%
• 1Y: 122.62%
• 3Y*: 132.61%
• 5Y*: 25.14%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KROS vs. RCAT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KROS

KROS Risk / Return Rank: 44
KROS Sharpe Ratio Rank: 47
KROS Sortino Ratio Rank: 45
KROS Omega Ratio Rank: 45
KROS Calmar Ratio Rank: 42
KROS Martin Ratio Rank: 43

RCAT

RCAT Risk / Return Rank: 77
RCAT Sharpe Ratio Rank: 76
RCAT Sortino Ratio Rank: 80
RCAT Omega Ratio Rank: 74
RCAT Calmar Ratio Rank: 78
RCAT Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KROS vs. RCAT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Keros Therapeutics, Inc. (KROS) and Red Cat Holdings, Inc. (RCAT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KROS	RCAT	Difference
Sharpe ratio Return per unit of total volatility	0.17	1.03	-0.85
Sortino ratio Return per unit of downside risk	0.62	2.03	-1.41
Omega ratio Gain probability vs. loss probability	1.08	1.23	-0.16
Calmar ratio Return relative to maximum drawdown	0.05	2.03	-1.99
Martin ratio Return relative to average drawdown	0.14	4.43	-4.29
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KROS vs. RCAT - Sharpe Ratio Comparison

The current KROS Sharpe Ratio is 0.17, which is lower than the RCAT Sharpe Ratio of 1.03. The chart below compares the historical Sharpe Ratios of KROS and RCAT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KROS	RCAT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.17	1.03	-0.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.42	0.22	-0.64
Sharpe Ratio (All Time) Calculated using the full available price history	-0.14	-0.06	-0.08

Correlation

The correlation between KROS and RCAT is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KROS vs. RCAT - Dividend Comparison

Neither KROS nor RCAT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

KROS vs. RCAT - Drawdown Comparison

The maximum KROS drawdown since its inception was -88.46%, smaller than the maximum RCAT drawdown of -99.76%. Use the drawdown chart below to compare losses from any high point for KROS and RCAT.

Drawdown Indicators

	KROS	RCAT	Difference
Max Drawdown Largest peak-to-trough decline	-88.46%	-99.76%	+11.30%
Max Drawdown (1Y) Largest decline over 1 year	-51.42%	-60.08%	+8.66%
Max Drawdown (5Y) Largest decline over 5 years	-86.45%	-92.25%	+5.80%
Current Drawdown Current decline from peak	-86.66%	-92.15%	+5.49%
Average Drawdown Average peak-to-trough decline	-47.26%	-95.58%	+48.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.76%	27.61%	-10.85%

Volatility

KROS vs. RCAT - Volatility Comparison

The current volatility for Keros Therapeutics, Inc. (KROS) is 19.72%, while Red Cat Holdings, Inc. (RCAT) has a volatility of 37.54%. This indicates that KROS experiences smaller price fluctuations and is considered to be less risky than RCAT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KROS	RCAT	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.72%	37.54%	-17.82%
Volatility (6M) Calculated over the trailing 6-month period	36.41%	84.17%	-47.76%
Volatility (1Y) Calculated over the trailing 1-year period	48.82%	120.21%	-71.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.56%	114.24%	-45.68%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.16%	251.41%	-181.25%

Financials